The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

Jennifer E. Joh, Nicole N. Esposito, John V. Kiluk, Christine Laronga, M. CATHERINE LEE, Loretta Loftus, Hatem Soliman, Judy C Boughey, Carol Reynolds, Homas J. Lawton, Peter I. Acs, Lucio Gordan, Acs Geza

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor-positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores (RS) on chemotherapy recommendations and to compare the estimated recurrence risk predicted by breast oncology specialists to RS. Methods. One hundred fifty-four patients with ERpositive early stage breast cancer and available RS results were selected. Clinicopathologic data were provided to four surgeons, four medical oncologists, and four pathologists. Participants were asked to estimate recurrence risk category and offer their chemotherapy recommendations initially without and later with knowledge of RS results. The three most important clinicopathologic features guiding their recommendations were requested. Results. Ninety-five (61.7%), 45 (29.2%), and 14 (9.1%) tumors were low, intermediate, and high risk by RS, respectively. RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2% ± 2.3% of cases. Without and with knowledge of RS, 82.3% ± 1.3% and 69.0% ± 6.9% of patients may be overtreated, respectively (p 0.0322). Inclusion of RS data resulted in a 24.9% change in treatment recommendations. There was no significant difference in recommendations between groups of participants. Conclusions. Breast oncology specialists tended to overestimate the risk of tumor recurrence compared with RS.

Original languageEnglish (US)
Pages (from-to)1520-1526
Number of pages7
JournalOncologist
Volume16
Issue number11
DOIs
StatePublished - 2011

Fingerprint

Estrogen Receptors
Breast Neoplasms
Recurrence
Therapeutics
Breast
ErbB-2 Receptor
Drug Therapy
Neoplasms
Adjuvant Chemotherapy
Patient Selection

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Gene expression profiling
  • Risk assessment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. / Joh, Jennifer E.; Esposito, Nicole N.; Kiluk, John V.; Laronga, Christine; CATHERINE LEE, M.; Loftus, Loretta; Soliman, Hatem; Boughey, Judy C; Reynolds, Carol; Lawton, Homas J.; Acs, Peter I.; Gordan, Lucio; Geza, Acs.

In: Oncologist, Vol. 16, No. 11, 2011, p. 1520-1526.

Research output: Contribution to journalArticle

Joh, Jennifer E. ; Esposito, Nicole N. ; Kiluk, John V. ; Laronga, Christine ; CATHERINE LEE, M. ; Loftus, Loretta ; Soliman, Hatem ; Boughey, Judy C ; Reynolds, Carol ; Lawton, Homas J. ; Acs, Peter I. ; Gordan, Lucio ; Geza, Acs. / The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. In: Oncologist. 2011 ; Vol. 16, No. 11. pp. 1520-1526.
@article{c1dcfef0c1064865b3b21f56805ace8c,
title = "The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists",
abstract = "Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor-positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores (RS) on chemotherapy recommendations and to compare the estimated recurrence risk predicted by breast oncology specialists to RS. Methods. One hundred fifty-four patients with ERpositive early stage breast cancer and available RS results were selected. Clinicopathologic data were provided to four surgeons, four medical oncologists, and four pathologists. Participants were asked to estimate recurrence risk category and offer their chemotherapy recommendations initially without and later with knowledge of RS results. The three most important clinicopathologic features guiding their recommendations were requested. Results. Ninety-five (61.7{\%}), 45 (29.2{\%}), and 14 (9.1{\%}) tumors were low, intermediate, and high risk by RS, respectively. RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2{\%} ± 2.3{\%} of cases. Without and with knowledge of RS, 82.3{\%} ± 1.3{\%} and 69.0{\%} ± 6.9{\%} of patients may be overtreated, respectively (p 0.0322). Inclusion of RS data resulted in a 24.9{\%} change in treatment recommendations. There was no significant difference in recommendations between groups of participants. Conclusions. Breast oncology specialists tended to overestimate the risk of tumor recurrence compared with RS.",
keywords = "Adjuvant chemotherapy, Breast cancer, Gene expression profiling, Risk assessment",
author = "Joh, {Jennifer E.} and Esposito, {Nicole N.} and Kiluk, {John V.} and Christine Laronga and {CATHERINE LEE}, M. and Loretta Loftus and Hatem Soliman and Boughey, {Judy C} and Carol Reynolds and Lawton, {Homas J.} and Acs, {Peter I.} and Lucio Gordan and Acs Geza",
year = "2011",
doi = "10.1634/theoncologist.2011-0045",
language = "English (US)",
volume = "16",
pages = "1520--1526",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "11",

}

TY - JOUR

T1 - The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

AU - Joh, Jennifer E.

AU - Esposito, Nicole N.

AU - Kiluk, John V.

AU - Laronga, Christine

AU - CATHERINE LEE, M.

AU - Loftus, Loretta

AU - Soliman, Hatem

AU - Boughey, Judy C

AU - Reynolds, Carol

AU - Lawton, Homas J.

AU - Acs, Peter I.

AU - Gordan, Lucio

AU - Geza, Acs

PY - 2011

Y1 - 2011

N2 - Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor-positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores (RS) on chemotherapy recommendations and to compare the estimated recurrence risk predicted by breast oncology specialists to RS. Methods. One hundred fifty-four patients with ERpositive early stage breast cancer and available RS results were selected. Clinicopathologic data were provided to four surgeons, four medical oncologists, and four pathologists. Participants were asked to estimate recurrence risk category and offer their chemotherapy recommendations initially without and later with knowledge of RS results. The three most important clinicopathologic features guiding their recommendations were requested. Results. Ninety-five (61.7%), 45 (29.2%), and 14 (9.1%) tumors were low, intermediate, and high risk by RS, respectively. RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2% ± 2.3% of cases. Without and with knowledge of RS, 82.3% ± 1.3% and 69.0% ± 6.9% of patients may be overtreated, respectively (p 0.0322). Inclusion of RS data resulted in a 24.9% change in treatment recommendations. There was no significant difference in recommendations between groups of participants. Conclusions. Breast oncology specialists tended to overestimate the risk of tumor recurrence compared with RS.

AB - Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor-positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores (RS) on chemotherapy recommendations and to compare the estimated recurrence risk predicted by breast oncology specialists to RS. Methods. One hundred fifty-four patients with ERpositive early stage breast cancer and available RS results were selected. Clinicopathologic data were provided to four surgeons, four medical oncologists, and four pathologists. Participants were asked to estimate recurrence risk category and offer their chemotherapy recommendations initially without and later with knowledge of RS results. The three most important clinicopathologic features guiding their recommendations were requested. Results. Ninety-five (61.7%), 45 (29.2%), and 14 (9.1%) tumors were low, intermediate, and high risk by RS, respectively. RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2% ± 2.3% of cases. Without and with knowledge of RS, 82.3% ± 1.3% and 69.0% ± 6.9% of patients may be overtreated, respectively (p 0.0322). Inclusion of RS data resulted in a 24.9% change in treatment recommendations. There was no significant difference in recommendations between groups of participants. Conclusions. Breast oncology specialists tended to overestimate the risk of tumor recurrence compared with RS.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Gene expression profiling

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=82355164800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355164800&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2011-0045

DO - 10.1634/theoncologist.2011-0045

M3 - Article

C2 - 22016474

AN - SCOPUS:82355164800

VL - 16

SP - 1520

EP - 1526

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 11

ER -